Introduction: A large number of COVID-19 patients are in recovery, and millions of people are vaccinated for COVID-19 globally. This calls for a rapid screening strategy of SARS-CoV-2 protective antibodies, generated in rehabilitated and vaccinated populations.
Methods: Serum samples collected over a follow-up period of six months from 306 COVID-19 cases discharged from Wuhan Tongji Hospital were analyzed. Anti-S Abs were detected by colloidal gold immunochromatographic assay (GICA), and neutralizing antibodies (nAbs) were detected by chemiluminescent microparticle immunoassay (CMIA).
Results: Most COVID-19 survivors tested positive for anti-S Abs (83.7%) and nAbs (98.0%) 6 months after being discharged from the hospital, and the levels of anti-S Abs in the blood were highly positively correlated with nAbs (r = 0.652, P < 0.0001). The positivity rate of nAbs for patients with anti-S Abs positive was 100%.
Conclusions: There is a good agreement between anti-S Abs detected by GICA and nAbs detected by CMIA. It indicates that anti-S Abs detected by GICA may be used as a cheaper screening strategy for detectable SARS-CoV-2 nAbs in COVID-19 convalescent individuals.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180344 | PMC |
| http://dx.doi.org/10.1016/j.ijid.2021.05.080 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-TNF therapy impairs both short- and long-term IgG responses after repeated vaccination.
Allergy
February 2025
Laboratories of Immunology and Antibody Glycan Analysis, Institute of Nutritional Medicine, University of Lübeck and University Medical Center Schleswig-Holstein, Lübeck, Germany.
Background: Recently, it has been questioned whether vaccination of patients with inflammatory (auto)immune diseases under anti-tumor necrosis factor (TNF) treatment leads to impaired vaccine-induced immune responses and protection against breakthrough infections. However, the effects of TNF blockade on short- and long-term immune responses after repeated vaccination remain unclear. Vaccination studies have shown that initial short-term IgG antibodies (Abs) carry highly galactosylated and sialylated Fc glycans, whilst long-term IgG Abs have low levels of galactosylation and sialylation and are most likely generated by long-lived plasma cells (PCs) derived primarily from the germinal center (GC) response.
View Article and Find Full Text PDFEvorpacept-Induced Interference and Application of a Novel Mitigation Agent, Evo-NR, in Pretransfusion Testing.
Transfus Med Hemother
June 2024
Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Introduction: Evorpacept is a CD47-blocking agent currently being developed for the treatment of various cancers. Interference by evorpacept in pretransfusion compatibility testing has been reported at limited plasma concentrations. Although various mitigation strategies have been proposed, none are practical.
View Article and Find Full Text PDFAnti_spike and anti_nucleocapsid IgG responses to SARS-CoV-2 in children of Jordan.
Heliyon
May 2024
Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan.
Article Synopsis
- Children in Jordan show high levels of anti-S and anti-N antibodies against COVID-19, indicating strong immune responses, especially in those over 12 years old.
- A study involving 151 unvaccinated children revealed that a majority tested positive for these antibodies, with older children exhibiting higher concentrations than younger ones.
- Overall, while children's anti-S levels were found to be higher than those of naturally infected unvaccinated adults, adults had significantly greater anti-N antibody levels, suggesting different immune response dynamics across age groups.
Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients.
J Clin Virol
November 2023
Clinic of Infectious Diseases, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Article Synopsis
- - Tixagevimab-cilgavimab is approved for immunocompromised patients as a preventive treatment, even amid the spread of the Omicron variant (specifically BA.5) and serves as support or an alternative to vaccination.
- - The study measured neutralizing antibody levels in fully vaccinated immunocompromised patients following treatment, finding that only 12.5% achieved adequate antibody levels against BA.5, while most had lower responses compared to another variant.
- - The results indicate that tixagevimab-cilgavimab should not replace vaccination but may be beneficial as a supplementary treatment if the dosage is increased.
Anti-SARS-CoV-2 (COVID-19) vaccination efficacy in patients with severe neuromuscular diseases.
Rev Neurol (Paris)
November 2023
Neuromuscular Reference Center AOC, Neurology and Neuromuscular Diseases Department, Pellegrin Hospital, Bordeaux University Hospitals, Bordeaux, France. Electronic address:
Introduction: Patients with severe neuromuscular disease (sNMD) are considered at high risk of severe COVID-19. Muscle tissue is often replaced by fibroadipose tissue in these diseases whereas the new mRNA-based vaccines are injected intramuscularly. We aimed at evaluating the efficacy of two injections associated with a booster injection of mRNA vaccine in these patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!